Latest Bio Protocol News: Exchange Listing & Launchpad

Bio Protocol released a weekly update on October 21, 2025, detailing progress in its ecosystem, including a token listing on a major Korean exchange and reflections on its launchpad activities. 

The update, posted on X by the account @BioProtocol, covered topics such as the chief product officer's review of the first Bio V2 launch season, advancements in intellectual property pipelines, the $BIO token's listing on Upbit, and the origins of the VitaSTEM project generated by an AI co-scientist. 

Background on Bio Protocol

Bio Protocol operates as a decentralized science platform that uses blockchain to support funding, development, and sharing of biotechnology innovations. Established in 2021 with connections to initiatives like VitaDAO, the platform addresses challenges in traditional biotech funding, particularly in high-risk fields such as rare diseases and longevity research. It allows researchers, patients, and cryptocurrency users to form AI-driven networks that automate research processes and provide milestone-based incentives with transparency.

Project Timeline Milestones:

• August 2021: Funded its first onchain science project in collaboration with the University of Copenhagen.
• June 2023: Launched its initial intellectual property token from Newcastle University.
• November 2023: Aggregate market capitalization of BioDAO tokens surpassed $200 million.
• December 2023: HairDAO submitted the first scientific patent from a decentralized autonomous organization.
• November 2024: Binance Labs invested Bio Protocol, and the BIO Genesis initiative raised over $33 million.
• September 2025: Secured $6.9 million from Maelstrom to develop an AI-native decentralized science platform.

Investors in Bio Protocol:

• Binance Labs: Marked this as its first investment in decentralized science.
• Pfizer Ventures: Through a $4.1 million round for VitaDAO in 2022.
• Maelstrom.

The team consists of specialists in tokenomics, research and development, legal affairs, product management, growth strategies, operations, marketing, artificial intelligence, and overall strategy. Leadership includes Paul Kohlhaas handling tokenomics and James Sinka overseeing research and development, along with community engagement. Advisors such as Tyler Golato for research and Vincent Weisser for AI and research contribute to the project's direction.

The platform runs on blockchains including Base and Solana, chosen for their speed and low transaction costs, supporting cross-chain operations. Additionally, it focuses on making biotechnology processes more open and efficient by using community-led funding and AI tools to reduce drug development timelines from years to months.

Key Developments in Bio Protocol

Weekly Update Overview: The October 21, 2025, update highlighted events from the preceding week. Clemens Ortlepp, the chief product officer, reviewed the first launch season of Bio V2 Launchpad, noting participation from more than 8,000 users and outlining plans for a second season with refinements. This ties into broader goals of integrating dozens of BioAgents and communities by the end of 2025's fourth quarter.

Intellectual Property Pipeline Advancements: The intellectual property pipeline showed advancements, including human trials and real-world pilots in areas like longevity, with over 125 experiments funded through Pump Science, neuroscience via NEURONGale for Alzheimer's, post-traumatic stress disorder through Spectruth DAO, and other fields. Projects such as Aubrai Terminal and Cerebrum DAO are in beta testing phases.

$BIO Token Listing on Upbit: The $BIO token listed on Upbit, South Korea's largest cryptocurrency exchange, on October 20, 2025, concluding a month-long tour in Asia. The exchange currently has the highest $BIO trading percentage in terms of 24-hour Volume. 

VitaSTEM Intellectual Property Token: VitaSTEM represents the first intellectual property token created entirely by a BioAgent, specifically Aubrai from VitaDAO, targeting rejuvenation of blood-forming stem cells to address aging without transplants. Launched through an ignition sale on October 6, 2025, it was oversubscribed by 4.9 times. The AI component processed more than 850,000 transcriptomes and identified over 100 genes.

Additional Account Updates: The @BioProtocol account spotlighted Curetopia, a DAO for rare diseases, and its team, including Ethan Perlstein, who holds a doctorate and founded Perlara. 

Conclusion

Bio Protocol's ecosystem demonstrates capabilities in combining blockchain, AI, and biotechnology to fund and advance research through mechanisms like BioDAOs, IP tokens, BioAgents, and the Launchpad. The recent Upbit listing and VitaSTEM project illustrate how the platform directs liquidity toward specific scientific outcomes, such as stem cell rejuvenation and human trials in longevity and neuroscience. 

With over $50 million allocated to labs and more than 125 million $BIO tokens staked, the system supports transparent, milestone-driven progress. Researchers and investors interested in decentralized science should examine the platform's tools for potential involvement, as they provide structured ways to contribute to and benefit from biotech developments. For more information about Bio Protocol and how it works, refer to our recent overview of the platform. 

Sources:

• Bio Protocol Raises $6.9M to Launch AI-Native Decentralized Science Platform: https://www.morningstar.com/news/pr-newswire/20250917ln75761/bio-protocol-raises-69m-to-launch-ai-native-decentralized-science-platform-for-biotech-funding-drug-discovery 

• Bio Protocol Website: https://www.bio.xyz/ 

• Bio Protocol Overview and Funding: https://www.panewslab.com/en/articles/pzyj45j8yc66 

• Bio Protocol Funding Round Led by Maelstorm: https://cointelegraph.com/news/maelstrom-animoca-back-protocol-s-bid-to-unite-ai-biotech-and-crypto